Cargando…

1051. Increased Mortality in Bacteremia by Enterobacter Species With Discordant Imipenem and Ertapenem Susceptibilities

BACKGROUND: Carbapenem-resistant Enterobacteriaceae (CRE) that are resistant only to one carbapenem have been reported, but the frequency of discordance between ertapenem and imipenem/meropenem is not known for Enterobacter species. We investigated the occurrence of discordant carbapenem susceptibil...

Descripción completa

Detalles Bibliográficos
Autores principales: Chou, Andrew, Rossi, Vittoria, Sucgang, Richard, Hamill, Richard, Zechiedrich, Lynn, Trautner, Barbara W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255083/
http://dx.doi.org/10.1093/ofid/ofy210.888
_version_ 1783373875314163712
author Chou, Andrew
Rossi, Vittoria
Sucgang, Richard
Hamill, Richard
Zechiedrich, Lynn
Trautner, Barbara W
author_facet Chou, Andrew
Rossi, Vittoria
Sucgang, Richard
Hamill, Richard
Zechiedrich, Lynn
Trautner, Barbara W
author_sort Chou, Andrew
collection PubMed
description BACKGROUND: Carbapenem-resistant Enterobacteriaceae (CRE) that are resistant only to one carbapenem have been reported, but the frequency of discordance between ertapenem and imipenem/meropenem is not known for Enterobacter species. We investigated the occurrence of discordant carbapenem susceptibilities in Enterobacter species bacteremia and the potential association with increased mortality. METHODS: We examined all cases of Enterobacter species bacteremia from January 2012 to December 2016 at the Michael E. DeBakey VA Medical Center in Houston, Texas, USA. Clinical and microbiological data were independently extracted by two investigators. Antibiotic susceptibility testing results were interpreted according to current CLSI breakpoints. RESULTS: We found 14/67 (20.9%) isolates had discordance between ertapenem and imipenem susceptibilities. Eight isolates were ertapenem susceptible/imipenem nonsusceptible and six isolates were ertapenem nonsusceptible/imipenem susceptible (table). Bacteremia cleared in 94.5% (52/55) of all patients who had follow-up cultures, including infection by all (13/13) isolates with discordant carbapenem susceptibilities tested. Thirty-day mortality was statistically higher in infection by isolates with discordant carbapenem susceptibilities than by isolates that were susceptible to all tested carbapenems (10% vs. 36%; P = 0.03, Fisher’s exact test). In-hospital mortality was also higher in the discordant cohort as well (12% vs. 36%; P = 0.04, Fisher’s exact test). Acute severity of illness at bacteremia onset did not differ between the groups (median Pitt bacteremia score 2 vs. 3; P = 0.11, Wilcoxon rank-sum test). CONCLUSION: Bacteremia by Enterobacter species with discordant ertapenem and imipenem/meropenem susceptibilities is a relevant clinical issue, occurring in 20.9% of Enterobacter species bacteremias at our institution, and the discordance is associated with increased mortality. Whether such species can be safely treated with one carbapenem but not another is worth further investigation. MIC: minimum inhibitory concentration; S: susceptible; I: intermediate; R: resistant; DISCLOSURES: B. W. Trautner, Paratek: Consultant, Consulting fee. Zambon: Consultant, Consulting fee and Research grant.
format Online
Article
Text
id pubmed-6255083
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62550832018-11-28 1051. Increased Mortality in Bacteremia by Enterobacter Species With Discordant Imipenem and Ertapenem Susceptibilities Chou, Andrew Rossi, Vittoria Sucgang, Richard Hamill, Richard Zechiedrich, Lynn Trautner, Barbara W Open Forum Infect Dis Abstracts BACKGROUND: Carbapenem-resistant Enterobacteriaceae (CRE) that are resistant only to one carbapenem have been reported, but the frequency of discordance between ertapenem and imipenem/meropenem is not known for Enterobacter species. We investigated the occurrence of discordant carbapenem susceptibilities in Enterobacter species bacteremia and the potential association with increased mortality. METHODS: We examined all cases of Enterobacter species bacteremia from January 2012 to December 2016 at the Michael E. DeBakey VA Medical Center in Houston, Texas, USA. Clinical and microbiological data were independently extracted by two investigators. Antibiotic susceptibility testing results were interpreted according to current CLSI breakpoints. RESULTS: We found 14/67 (20.9%) isolates had discordance between ertapenem and imipenem susceptibilities. Eight isolates were ertapenem susceptible/imipenem nonsusceptible and six isolates were ertapenem nonsusceptible/imipenem susceptible (table). Bacteremia cleared in 94.5% (52/55) of all patients who had follow-up cultures, including infection by all (13/13) isolates with discordant carbapenem susceptibilities tested. Thirty-day mortality was statistically higher in infection by isolates with discordant carbapenem susceptibilities than by isolates that were susceptible to all tested carbapenems (10% vs. 36%; P = 0.03, Fisher’s exact test). In-hospital mortality was also higher in the discordant cohort as well (12% vs. 36%; P = 0.04, Fisher’s exact test). Acute severity of illness at bacteremia onset did not differ between the groups (median Pitt bacteremia score 2 vs. 3; P = 0.11, Wilcoxon rank-sum test). CONCLUSION: Bacteremia by Enterobacter species with discordant ertapenem and imipenem/meropenem susceptibilities is a relevant clinical issue, occurring in 20.9% of Enterobacter species bacteremias at our institution, and the discordance is associated with increased mortality. Whether such species can be safely treated with one carbapenem but not another is worth further investigation. MIC: minimum inhibitory concentration; S: susceptible; I: intermediate; R: resistant; DISCLOSURES: B. W. Trautner, Paratek: Consultant, Consulting fee. Zambon: Consultant, Consulting fee and Research grant. Oxford University Press 2018-11-26 /pmc/articles/PMC6255083/ http://dx.doi.org/10.1093/ofid/ofy210.888 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Chou, Andrew
Rossi, Vittoria
Sucgang, Richard
Hamill, Richard
Zechiedrich, Lynn
Trautner, Barbara W
1051. Increased Mortality in Bacteremia by Enterobacter Species With Discordant Imipenem and Ertapenem Susceptibilities
title 1051. Increased Mortality in Bacteremia by Enterobacter Species With Discordant Imipenem and Ertapenem Susceptibilities
title_full 1051. Increased Mortality in Bacteremia by Enterobacter Species With Discordant Imipenem and Ertapenem Susceptibilities
title_fullStr 1051. Increased Mortality in Bacteremia by Enterobacter Species With Discordant Imipenem and Ertapenem Susceptibilities
title_full_unstemmed 1051. Increased Mortality in Bacteremia by Enterobacter Species With Discordant Imipenem and Ertapenem Susceptibilities
title_short 1051. Increased Mortality in Bacteremia by Enterobacter Species With Discordant Imipenem and Ertapenem Susceptibilities
title_sort 1051. increased mortality in bacteremia by enterobacter species with discordant imipenem and ertapenem susceptibilities
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255083/
http://dx.doi.org/10.1093/ofid/ofy210.888
work_keys_str_mv AT chouandrew 1051increasedmortalityinbacteremiabyenterobacterspecieswithdiscordantimipenemandertapenemsusceptibilities
AT rossivittoria 1051increasedmortalityinbacteremiabyenterobacterspecieswithdiscordantimipenemandertapenemsusceptibilities
AT sucgangrichard 1051increasedmortalityinbacteremiabyenterobacterspecieswithdiscordantimipenemandertapenemsusceptibilities
AT hamillrichard 1051increasedmortalityinbacteremiabyenterobacterspecieswithdiscordantimipenemandertapenemsusceptibilities
AT zechiedrichlynn 1051increasedmortalityinbacteremiabyenterobacterspecieswithdiscordantimipenemandertapenemsusceptibilities
AT trautnerbarbaraw 1051increasedmortalityinbacteremiabyenterobacterspecieswithdiscordantimipenemandertapenemsusceptibilities